Ticker > Company >

Aurobindo Pharma share price

Aurobindo Pharma Ltd.

NSE: AUROPHARMA BSE: 524804 SECTOR: Pharmaceuticals & Drugs  2.61 L   1.23 K   289

1027.70
0 0
BSE: 29 Aug 04:01 PM

Price Summary

Today's High

₹ 1040

Today's Low

₹ 1020.55

52 Week High

₹ 1592.55

52 Week Low

₹ 994.35

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

59688.98 Cr.

Enterprise Value

64015.71 Cr.

No. of Shares

58.08 Cr.

P/E

30.19

P/B

2.83

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  363.17

CASH

298.36 Cr.

DEBT

4625.09 Cr.

Promoter Holding

51.82 %

EPS (TTM)

₹  34.04

Sales Growth

2.7%

ROE

8.68 %

ROCE

10.85%

Profit Growth

-8.07 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Aurobindo Pharma Ltd.

Molnaflu Imdur Betaloc Seloken Ramace Plendil RHINOCORT Prostodin MERONEM XyloCaine SensorCaine Iressa Casodex CRESTOR Cold-EEZE MidNite Geritol Vivarin Enoxaklot Doripure Aurosakro Lecarpon Levospec Moxirobe Ibadenz Viatuff Fery-tasty Renor Rinoban Benzer Autidine Diclor Kenalac Ketohist Zmox Plus Actralika Nevirex Nelvex Indivex Celdol Ad 500 Zmox Pryde Diceta Otacut Tripcut Helicut Freeoxy Flumox Aurox Zolcer Kit Clarion Oxyfree Auronim Sf Auronim Md

Index Presence

The company is present in 34Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year2.7%
3 Year-1.06%
5 Year-3.95%

Profit Growth

1 Year-10.61%
3 Year6.29%
5 Year-1.43%

ROE%

1 Year8.68%
3 Year8.6%
5 Year11.22%

ROCE %

1 Year10.85%
3 Year10.24%
5 Year12.45%

Debt/Equity

0.2252

Price to Cash Flow

36.27

Interest Cover Ratio

11.2523

CFO/PAT (5 Yr. Avg.)

1.25815825427106

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 51.82 17.08
Mar 2025 51.82 16.92
Dec 2024 51.82 17.83
Sep 2024 51.82 20.39
Jun 2024 51.80 20.88
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 11.2523.
  • The Company has been maintaining an effective average operating margins of 20.0824270655938% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 74.979 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.25815825427106.

 Limitations

  • The company has shown a poor profit growth of 6.28894366488646% for the Past 3 years.
  • The company has shown a poor revenue growth of -1.05606829481567% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 2460.09 2824.59 2916.63 2731.99 2848.17
Total Expenditure 1961.16 2103.71 2203.48 2135.48 2051.83
Operating Profit 498.93 720.88 713.15 596.51 796.34
Other Income 65.32 122.66 54.26 113.98 83.77
Interest 51.13 51.63 66.19 61.09 60
Depreciation 66.88 68.16 68.28 93.88 70.02
Exceptional Items 0 0 0 0 0
Profit Before Tax 446.24 723.75 632.94 555.52 750.09
Tax 117.2 186.22 160.89 147.35 190.96
Profit After Tax 329.04 537.53 472.05 408.17 559.13
Adjusted EPS (Rs) 5.62 9.26 8.13 7.03 9.63

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 15823.68 11287.14 8457 10645.64 10933.3
Total Expenditure 11703.85 9831.6 6952.09 8421.6 8375.73
Operating Profit 4119.83 1455.54 1504.91 2224.04 2557.57
Other Income 589.86 688.85 443.92 616.06 328.12
Interest 28.68 16.94 74.58 182.6 230.04
Depreciation 488 415.26 243.26 254.58 297.2
Exceptional Items 0 -74.71 0 0 0
Profit Before Tax 4193.01 1637.48 1630.99 2402.92 2358.45
Tax 1080.1 182.77 388.82 502.82 611.66
Net Profit 3112.91 1454.71 1227.11 1954.14 1746.79
Adjusted EPS (Rs.) 53.13 24.83 21.2 32.43 30.08

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 58.59 58.59 58.59 58.59 58.08
Total Reserves 15866.02 17058.75 17975.44 19664.23 20476.03
Borrowings 0 0 0 0 400
Other N/C liabilities 1412.13 4566.44 3138.49 3399.83 3975.54
Current liabilities 6756.58 4180.97 6993.24 5746.81 6984.21
Total Liabilities 24093.32 25864.75 28165.76 28869.46 31893.86
Assets
Net Block 4472.07 3585.83 3687.5 2419.13 2336.8
Capital WIP 719.02 225.15 239.09 132.68 87.53
Intangible WIP 15.87 0 0 0 0
Investments 4880.89 6584.35 8105.36 13393.43 15209.56
Loans & Advances 1610.41 5605.43 5800.45 5012.1 5853.44
Other N/C Assets 59.05 28.88 53.78 170.92 153.42
Current Assets 12336.01 9835.11 10279.58 7741.2 8253.11
Total Assets 24093.32 25864.75 28165.76 28869.46 31893.86
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 4193.01 1637.48 1611.23 2475.41 2358.45
Adjustment 53.15 -30.65 175.2 69.61 284.12
Changes in Assets & Liabilities -624.78 2811.95 330.37 -228.04 -327.62
Tax Paid -626.85 -692.07 -300.63 -602.18 -669.16
Operating Cash Flow 2994.53 3726.71 1816.17 1714.8 1645.79
Investing Cash Flow -2650.24 -1614.54 -3229.65 -151.58 -2050.16
Financing Cash Flow -28.06 -2447.54 1719.48 -1837.03 616.31
Net Cash Flow 316.23 -335.37 306 -273.81 211.94

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 51.80 51.82 51.82 51.82 51.82
axis clinicals limited 0.11 0.11 0.11 0.11 0.11
axis clinicals limited, t... 2.85 2.85 2.85 2.85 2.85
k spoorthi - 1.19 1.19 - 1.19
k nityananda reddy 4.33 4.37 - - 4.37
kirthi reddy kambam 3.46 3.45 3.45 3.45 3.45
m sivakumaran 2.47 2.47 2.47 2.47 2.47
m sumanth kumar reddy 0.27 0.27 0.27 0.27 0.27
prasada reddy kambham 0.05 0.05 0.05 0.05 0.05
rajeswari kambam - - 0.31 - 0.31
rpr sons advisors private... 33.51 33.50 33.50 33.50 33.50
suneela rani penaka 0.02 0.02 0.02 0.02 0.02
trident chemphar limited 0.13 0.13 0.13 0.13 0.13
venkata ramprasad reddy p... 3.07 3.07 3.07 3.07 3.07
k rajeswari - 0.31 - 0.31 -
k spoorthi - - - 1.19 -
kambam nityananda reddy - - 4.37 4.37 -
kambam spoorthi 1.19 - - - -
rajeshwari kambam 0.31 - - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 48.20 48.18 48.18 48.18 48.18
hdfc trustee company ltd.... - - - - 3.92
icici prudential multicap... - - - - 3.50
investor education and pr... 0.14 0.15 - 0.15 0.16
life insurance corporatio... 2.78 2.08 2.08 2.45 2.49
mirae asset nifty india m... - - - - 2.70
hdfc mutual fund - hdfc s... - - - 4.33 -
icici prudential nifty ph... - - - 2.95 -
mirae asset large cap fun... - - - 2.52 -
nps trust- a/c icici prud... - 1.57 1.92 2.20 -
quant mutual fund-quant e... - - - 3.99 -
hdfc mutual fund-hdfc arb... 4.34 - 4.33 - -
icici prudential s&p bse ... - - 2.94 - -
investor education and pr... - - 0.15 - -
mirae asset elss tax save... - - 2.43 - -
quant mutual fund - quant... - - 3.60 - -
hdfc large and mid cap fu... - 4.42 - - -
icici prudential manufact... - 3.17 - - -
mirae asset nifty midcap ... - 2.34 - - -
quant mutual fund - quant... 3.27 3.60 - - -
icici prudential regular ... 4.20 - - - -
mirae asset nifty 200 alp... 2.69 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit INDIA RATINGS & RESEARCH
Credit FITCH
TYPE AGENCY Link
TYPE AGENCY Link
Research Geojit
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research HDFC Securities
Research HDFC Securities
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Markets Ltd.
Research Motilal Oswal
Research Prabhudas Lilladhar
Research Nirmal Bang Institutional

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY23
Concall Q4FY22
Concall Q4FY22
Concall Q4FY21
Concall Q4FY20
Concall Q3FY25
Concall Q3FY24
Concall Q3FY23
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY23
Concall Q2FY21
Concall Q1FY24
Concall Q1FY24
Concall Q1FY23
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY23
Presentation Q4FY22
Presentation Q4FY21
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY25
Presentation Q2FY25
Presentation Q2FY24
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY22
Presentation Q1FY21

Company News

USFDA completes inspection at Aurobindo Pharma’s arm's API manufacturing facility in Telangana 30 Aug, 10:14 AM Aurobindo Pharma’s arm obtains marketing authorization for Dazublys in UK 26 Aug, 10:30 AM Aurobindo Pharma informs about disclosure 26 Aug, 9:57 AM Aurobindo Pharma informs about press release 20 Aug, 3:27 PM Aurobindo Pharma - Quaterly Results 4 Aug, 7:26 PM Aurobindo Pharma - Quaterly Results 4 Aug, 7:26 PM Aurobindo Pharma’s arm to acquire 100% membership interest in Lannett Company LLC 31 Jul, 10:12 AM Aurobindo Pharma to manufacture, supply long-acting HIV treatment cabotegravir across 133 countries 15 Jul, 3:42 PM Aurobindo Pharma informs about compliance certificate 3 Jul, 3:37 PM Aurobindo Pharma’s arm obtains marketing authorization for Dazublys 3 Jul, 10:20 AM Aurobindo Pharma’s arm restarts Penicillin-G manufacturing facility in AP 30 Jun, 2:59 PM Aurobindo Pharma’s arm obtains marketing authorization from MHRA for Dyrupeg 25 Jun, 10:10 AM Aurobindo Pharma submits analyst meet intimation 20 Jun, 5:10 PM Aurobindo Pharma’s arm incorporates wholly owned subsidiary in USA 16 Jun, 9:29 AM Aurobindo Pharma’s arm incorporates wholly owned subsidiary in Netherlands 28 May, 6:02 PM Aurobindo Pharma - Quaterly Results 26 May, 7:34 PM Aurobindo Pharma - Quaterly Results 26 May, 7:34 PM Aurobindo Pharma’s arm obtains marketing authorisation from MHRA for biosimilar Zefylti 14 May, 9:24 AM Aurobindo Pharma informs about press release 26 Apr, 10:18 AM Aurobindo Pharma’s arm gets USFDA's nod to manufacture, market Dasatinib tablets 23 Apr, 2:41 PM Aurobindo Pharma submits press release 14 Apr, 12:29 PM Aurobindo Pharma gets USFDA’s nod to manufacture, market Rivaroxaban Tablets USP 14 Apr, 9:44 AM USFDA concludes inspection at Raleigh plant of Aurobindo Pharma’s arm 12 Apr, 12:18 PM Aurobindo Pharma’s arm gets marketing authorization for Dyrupeg 7 Apr, 11:30 AM Aurobindo Pharma informs about disclosure 31 Mar, 4:48 PM Aurobindo Pharma informs about termination of license agreement 5 Mar, 10:15 AM Aurobindo Pharma acquires 80% stake in Tergene Biotech 1 Mar, 12:31 PM USFDA completes inspection at Andhra Pradesh facility of Aurobindo Pharma’s arm 19 Feb, 10:10 AM Aurobindo Pharma informs about analyst meet 18 Feb, 2:11 PM Aurobindo Pharma to commence supplies to Europe from China facility from April 17 Feb, 11:10 AM Aurobindo Pharma’s arm gets marketing authorization for Zefylti 14 Feb, 11:38 AM Aurobindo Pharma reports 10% fall in Q3 consolidated net profit 7 Feb, 2:39 PM Aurobindo Pharma informs about integrated filing 7 Feb, 12:44 PM Aurobindo Pharma - Quaterly Results 6 Feb, 7:56 PM Aurobindo Pharma - Quaterly Results 6 Feb, 7:56 PM Aurobindo Pharma informs about new orders 29 Jan, 2:56 PM Aurobindo Pharma informs about analyst meet 28 Jan, 3:08 PM Aurobindo Pharma informs about updates 28 Jan, 11:26 AM Aurobindo Pharma informs about board meeting 17 Jan, 2:22 PM Aurobindo Pharma informs about certificate 6 Jan, 11:16 AM Aurobindo Pharma’s step-down arm gets UK’s MHRA’s nod for Bevqolva 21 Dec, 4:32 PM Aurobindo Pharma informs about press release 21 Dec, 3:50 PM USFDA completes inspection at API manufacturing facility of Aurobindo Pharma’s arm 18 Dec, 10:51 AM Aurobindo Pharma’s arm recalling over 1 lakh bottles of Cinacalcet tablets in multiple strengths 16 Dec, 9:49 AM Aurobindo Pharma’s arm gets USFDA’s approval for Pazopanib Tablets 5 Dec, 4:28 PM Aurobindo Pharma’s arm enters into agreement with global pharma major 25 Nov, 9:59 AM Aurobindo Pharma informs about company updates 23 Nov, 3:34 PM Aurobindo Pharma informs about investor meet 21 Nov, 5:34 PM Aurobindo Pharma informs about earnings call transcript 18 Nov, 4:30 PM Aurobindo Pharma’s arm gets GMP certificate of compliance for Hyderabad facility 13 Nov, 10:59 AM

Aurobindo Pharma Stock Price Analysis and Quick Research Report. Is Aurobindo Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Aurobindo Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Aurobindo Pharma has a PE ratio of 30.1994000663981 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Aurobindo Pharma has ROA of 5.7495% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Aurobindo Pharma has a Current ratio of 1.1817.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Aurobindo Pharma has a ROE of 8.6782%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Aurobindo Pharma has a Debt to Equity ratio of 0.2252 which means that the company has low proportion of debt in its capital.

  • Sales growth: Aurobindo Pharma has reported revenue growth of 2.7021% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Aurobindo Pharma for the current financial year is 23.3924798551215%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Aurobindo Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Aurobindo Pharma is Rs 34.0371. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Aurobindo Pharma in Ticker for free. Also, one can get the intrinsic value of Aurobindo Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Aurobindo Pharma FAQs

Q1. What is Aurobindo Pharma share price today?
Ans: The current share price of Aurobindo Pharma is Rs 1027.9.

Q2. What is the market capitalisation of Aurobindo Pharma?
Ans: Aurobindo Pharma has a market capitalisation of Rs 59700.59882817 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Aurobindo Pharma?
Ans: The PE ratio of Aurobindo Pharma is 30.1994000663981 and the P/B ratio of Aurobindo Pharma is 2.83031908068461, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Aurobindo Pharma share?
Ans: The 52-week high share price of Aurobindo Pharma is Rs 1592, and the 52-week low share price of Aurobindo Pharma is Rs 1010.

Q5. Does Aurobindo Pharma pay dividends?
Ans: Currently, Aurobindo Pharma does not pay dividends. Dividend yield of Aurobindo Pharma is around 0%.

Q6. What are the face value and book value of Aurobindo Pharma shares?
Ans: The face value of Aurobindo Pharma shares is Rs 1, while the book value per share of Aurobindo Pharma is around Rs 363.1746. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Aurobindo Pharma?
Ans: Aurobindo Pharma has a total debt of Rs 4625.09 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Aurobindo Pharma?
Ans: The ROE of Aurobindo Pharma is 8.6782% and ROCE of Aurobindo Pharma is 10.8532%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Aurobindo Pharma a good buy for the long term?
Ans: The Aurobindo Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Aurobindo Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Aurobindo Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Aurobindo Pharma’s financials?
Ans: You can review Aurobindo Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Aurobindo Pharma

Aurobindo Pharma Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Welcome to our Aurobindo Pharma Ltd. stock analysis page, where long-term stock investors can find a comprehensive range of resources and tools to make well-informed investment decisions. Our platform offers an in-depth analysis of various aspects of Aurobindo Pharma's stock performance, allowing investors to gain valuable insights into the company's financial stability, growth potential, and viability as a long-term investment. Let's delve into each topic in detail.

Aurobindo Pharma Ltd. Share Price Analysis

Analyzing the share price of Aurobindo Pharma Ltd. is crucial for understanding the company's growth potential and market sentiment. Our pre-built screening tools enable investors to track the historical share price of the company over different timeframes. By studying price trends, trading volumes, trading range, and the stock's relative performance compared to market indices, investors gain insights into Aurobindo Pharma's financial stability, growth prospects, and viability as a long-term investment. For a more comprehensive analysis, investors can leverage our premium features tools, such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, to evaluate the stock's intrinsic value and growth potential.

Aurobindo Pharma Ltd. Balance Sheet Evaluation

Evaluating the balance sheet of Aurobindo Pharma Ltd. is a critical step for long-term investors to understand the company's financial position and growth potential. Our pre-built screening tools enable investors to determine Aurobindo Pharma's balance sheet ratios and metrics. By examining key financial indicators, such as current assets, current liabilities, and long-term debt, investors gain insights into the company's financial stability, liquidity, and potential for growth. Our premium features tools, including DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, provide a more comprehensive analysis of Aurobindo Pharma's balance sheet, helping investors assess its long-term investment potential.

Aurobindo Pharma Ltd. Annual Report Insights

Aurobindo Pharma Ltd.'s annual reports offer a wealth of information about the company's performance, strategies, and plans. On our platform, you can access downloadable PDF versions of Aurobindo Pharma's annual reports, along with expert reviews and analysis. These annual reports provide insights into Aurobindo Pharma's business model, competitive landscape, and macroeconomic factors that may impact its operations. Coupled with our premium features tools, investors can conduct a thorough analysis and make well-informed decisions based on Aurobindo Pharma's annual report.

Aurobindo Pharma Ltd. Dividend Payments

Analyzing Aurobindo Pharma Ltd.'s dividend payments is crucial for long-term investors seeking stable returns. Our stock analysis page provides comprehensive data on the company's dividend payment history. By analyzing Aurobindo Pharma's profitability, dividend policy, and metrics such as the dividend yield and payout ratio, investors can make well-informed investment decisions. Our premium features tools, including DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, allow investors to evaluate the impact of dividends on Aurobindo Pharma's stock value and overall investment strategy.

Aurobindo Pharma Ltd. Quarterly Results Analysis

Analyzing Aurobindo Pharma Ltd.'s quarterly results helps investors evaluate its short-term performance and gauge its future growth potential. On our website, you can find downloadable PDF files of Aurobindo Pharma's quarterly results, allowing investors to assess the company's recent performance and key financial metrics, such as revenue growth, earnings per share, and margins. By leveraging our premium features tools and conducting a thorough analysis, long-term investors can make well-informed decisions regarding their investment positions in Aurobindo Pharma.

Aurobindo Pharma Ltd. Stock Price Trends

Analyzing Aurobindo Pharma Ltd.'s stock price trends is essential for understanding its growth potential and market sentiment. Our pre-built screening tools enable investors to track Aurobindo Pharma's stock price trends over different timeframes. This allows the identification of short-term and long-term patterns and pricing volatility. By utilizing our premium features tools, investors gain additional insights into factors affecting Aurobindo Pharma's stock performance, aiding them in making well-informed decisions about their long-term investment positions.

Aurobindo Pharma Ltd. Price Charts

Technical analysis through price chart analysis provides additional insights into Aurobindo Pharma Ltd.'s stock performance. On our website, you can access dynamic price charts that display historical price movements, technical indicators, and patterns. These charts assist investors in identifying potential entry and exit points, support and resistance levels, and trend reversals. By incorporating these insights into our premium features tools, investors can conduct a comprehensive analysis and make informed decisions about Aurobindo Pharma as a long-term investment.

Aurobindo Pharma Ltd. News Updates

Keeping up with the latest news and developments concerning Aurobindo Pharma Ltd. is fundamental for long-term investors. Our website provides comprehensive and timely information sourced from reliable news channels. Through articles and news updates, investors gain insights into Aurobindo Pharma's industry trends, market position, and future outlook. This information empowers investors to make well-informed decisions and stay ahead of market dynamics affecting their long-term investment positions in Aurobindo Pharma.

Aurobindo Pharma Ltd. Conference Calls

Aurobindo Pharma Ltd.'s conference calls offer crucial insights into the company's operations, financial performance, and growth strategies. On our platform, you can find a searchable collection of Aurobindo Pharma's conference calls, including downloadable recordings. By listening to these calls, investors gain a deep understanding of Aurobindo Pharma's management team, growth plans, and economic factors impacting the company's performance. Leveraging our premium features tools, investors can carry out comprehensive analyses and make well-informed decisions regarding their long-term investment positions in Aurobindo Pharma.

Aurobindo Pharma Ltd. Transcripts

Transcripts of Aurobindo Pharma Ltd.'s conference calls capture important discussions and insights. Our platform provides downloadable transcripts that include in-depth analyses of the company's financial performance, future plans, and market trends. Reviewing these transcripts offers valuable insights into Aurobindo Pharma's strategies, growth potential, and adaptability to market dynamics. By leveraging our premium features tools and conducting a comprehensive analysis, investors can make well-informed decisions about Aurobindo Pharma as a long-term investment.

Aurobindo Pharma Ltd. Investor Presentations

Aurobindo Pharma Ltd.'s investor presentations offer detailed information about the company's financials, strategic initiatives, and future plans. On our platform, you can easily access these investor presentations in downloadable PDF format. Investor presentations provide insights beyond the numbers, delving deep into Aurobindo Pharma's growth strategy, market expansion plans, and competitive advantages. By leveraging our premium features tools and pre-built screening tools, investors can perform a comprehensive analysis of Aurobindo Pharma and make sound investment decisions.

Aurobindo Pharma Ltd. Promoters and Shareholders

Understanding the ownership structure of Aurobindo Pharma Ltd. is crucial for long-term investors evaluating the company's growth potential and stability. Our pre-built screening tools enable investors to assess promoter holdings and analyze the company's shareholder base. By understanding the distribution of ownership and the alignment of interests, investors can make well-informed decisions about their long-term investment positions in Aurobindo Pharma.

Aurobindo Pharma Ltd. ROCE

The Return on Capital Employed (ROCE) is a key financial metric used to assess the profitability and efficiency of a company. It measures how effectively a company utilizes its capital to generate profits. By analyzing Aurobindo Pharma Ltd.'s ROCE, investors can evaluate the company's ability to generate returns from the capital employed in its operations. ROCE is calculated by dividing the operating profit by the capital employed. The ratio's data can be found in the financials table or ratio section on this page.

Aurobindo Pharma Ltd. EBITDA

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It provides a clearer picture of a company's operating performance by excluding non-operating expenses. Aurobindo Pharma Ltd.'s EBITDA serves as a useful measure to assess the company's profitability and cash flow generation. It helps investors understand the core earnings potential of the company's operations. The EBITDA data for Aurobindo Pharma Ltd. can be found in the financials table or ratio section on this page.

Aurobindo Pharma Ltd. DPS

DPS stands for Dividends Per Share, which is one of the key indicators of shareholder returns. Aurobindo Pharma Ltd.'s DPS reflects the amount of dividends distributed to shareholders per outstanding share. Investors often consider the DPS when assessing the company's dividend policy and its commitment to returning value to shareholders. The DPS data for Aurobindo Pharma Ltd. can be found in the financials table or ratio section on this page.

Aurobindo Pharma Ltd. EPS

EPS, or Earnings Per Share, is an important measure of a company's profitability and its ability to generate earnings for each outstanding share. Aurobindo Pharma Ltd.'s EPS provides insights into the company's net profits on a per-share basis. Investors often use EPS to compare companies within the same industry or to understand the company's growth potential. The EPS data for Aurobindo Pharma Ltd. can be found in the financials table or ratio section on this page.

Read More
X